BR112023002525A2 - Análogos de ham15-52 e composição farmacêutica - Google Patents

Análogos de ham15-52 e composição farmacêutica

Info

Publication number
BR112023002525A2
BR112023002525A2 BR112023002525A BR112023002525A BR112023002525A2 BR 112023002525 A2 BR112023002525 A2 BR 112023002525A2 BR 112023002525 A BR112023002525 A BR 112023002525A BR 112023002525 A BR112023002525 A BR 112023002525A BR 112023002525 A2 BR112023002525 A2 BR 112023002525A2
Authority
BR
Brazil
Prior art keywords
ham15
hamy3r
analogs
analogues
pharmaceutical composition
Prior art date
Application number
BR112023002525A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Frøslev Nielsen Jens
Tobias Gustav Rigbolt Kristoffer
Matzen Bech Esben
Lundh Morten
Magotti Paola
Ballarín-González Borja
Ljungberg Pedersen Søren
Vrang Niels
Original Assignee
Gubra Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72659001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112023002525(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gubra Aps filed Critical Gubra Aps
Publication of BR112023002525A2 publication Critical patent/BR112023002525A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023002525A 2020-09-24 2021-09-23 Análogos de ham15-52 e composição farmacêutica BR112023002525A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20198117 2020-09-24
PCT/EP2021/076250 WO2022063925A1 (en) 2020-09-24 2021-09-23 Ham15-52 analogues with improved amylin receptor (hamy3r) potency

Publications (1)

Publication Number Publication Date
BR112023002525A2 true BR112023002525A2 (pt) 2023-04-04

Family

ID=72659001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002525A BR112023002525A2 (pt) 2020-09-24 2021-09-23 Análogos de ham15-52 e composição farmacêutica

Country Status (21)

Country Link
US (2) US12139520B2 (https=)
EP (1) EP4021929B1 (https=)
JP (1) JP2023544959A (https=)
KR (1) KR20230073176A (https=)
CN (1) CN116322741A (https=)
AU (1) AU2021350396A1 (https=)
BR (1) BR112023002525A2 (https=)
CA (1) CA3189267A1 (https=)
DK (1) DK4021929T5 (https=)
ES (1) ES2950137T3 (https=)
FI (1) FI4021929T3 (https=)
HR (1) HRP20230534T1 (https=)
HU (1) HUE062560T2 (https=)
IL (1) IL300620B2 (https=)
MX (1) MX2023002182A (https=)
PL (1) PL4021929T3 (https=)
PT (1) PT4021929T (https=)
RS (1) RS64256B1 (https=)
SI (1) SI4021929T1 (https=)
WO (1) WO2022063925A1 (https=)
ZA (1) ZA202301635B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815327B (zh) 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
IL317600B2 (en) 2022-07-01 2026-03-01 Gubra As Amylin receptor (HAMY3R) agonists with improved chemical stability
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
NZ579621A (en) * 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー/エス ポリペプチド
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
WO2019005623A1 (en) 2017-06-30 2019-01-03 Adepthera Llc PEPTIDE ANALOGS
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso

Also Published As

Publication number Publication date
CA3189267A1 (en) 2022-03-31
AU2021350396A1 (en) 2023-03-16
CN116322741A (zh) 2023-06-23
IL300620B2 (en) 2025-12-01
IL300620A (en) 2023-04-01
JP2023544959A (ja) 2023-10-26
ZA202301635B (en) 2024-03-27
HRP20230534T1 (hr) 2023-08-04
WO2022063925A1 (en) 2022-03-31
KR20230073176A (ko) 2023-05-25
HUE062560T2 (hu) 2023-11-28
RS64256B1 (sr) 2023-07-31
IL300620B1 (en) 2025-08-01
US20240101634A1 (en) 2024-03-28
PL4021929T3 (pl) 2023-07-31
FI4021929T3 (fi) 2023-06-14
PT4021929T (pt) 2023-06-21
SI4021929T1 (sl) 2023-09-29
ES2950137T3 (es) 2023-10-05
DK4021929T5 (da) 2024-07-29
MX2023002182A (es) 2023-11-16
DK4021929T3 (da) 2023-07-10
US12139520B2 (en) 2024-11-12
EP4021929B1 (en) 2023-04-26
US20250129134A1 (en) 2025-04-24
EP4021929A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
BR112023002525A2 (pt) Análogos de ham15-52 e composição farmacêutica
BR112023003168A2 (pt) Compostos como agonistas do glp-1r
CO2021012380A2 (es) Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
BR0315937A (pt) Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
BR112012012025A2 (pt) polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão
BR112022025416A2 (pt) Proteína doce de trufa
BRPI0717183B8 (pt) exendina ou análogo de exendina modificada por peg, composição e seu uso
BRPI0309689A2 (pt) formulação de uma mistura de flavonóides de anel-b-livre e flavanos como agente terapêutico.
BRPI0516237A (pt) derivado de pirimidina fundido com anel não aromático
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
BR112022023506A2 (pt) Composto, composição farmacêutica, uso do composto e método de uso de um composto
BR112012012081A2 (pt) método para o processamento de um arquivo de imagens médicas kobitidas em um procedimento de imagem guiada por protocolo ,equipamento para o processamento de um arquivo de imagens médicas obtidas por um procedimento de imagem guiada por protocolo e elemamto de programa de computador contendo conjuntos de instruções
PE20251395A1 (es) Proteinas de fusion de hmpv de prefusion estabilizadas
ECSP23036608A (es) Compuestos aromáticos que contienen boro y análogos de insulina
AR132698A1 (es) DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
BR112015009486A2 (pt) surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído
BR112022011504A2 (pt) Produtos e métodos de iogurte com alto teor de proteína
BR112022015232A2 (pt) Peptídeo cíclico, composição farmacêutica e solução aquosa de um peptídeo específico de receptor de melanocortina com um valor ec50 menor que 1 nm em cada dentre mc1r e mc5r
BRPI0507435A (pt) compostos de piperidinilcarbonilpirrolidinas, processos para a preparação do mesmo,composição farmacêutica e uso como agonistas de melanocortina
GUILLEMIN et al. Re-evaluation of a technique of pituitary incubation in vitro as an assay for corticotropin releasing factor
BR112023016083A2 (pt) Composições contendo análogos de incretina e seus usos
BR112022020956A8 (pt) Análogos de peptídeo tirosina tirosina (pyy) de ação prolongada e métodos de uso

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GUBRA A/S (DK)